Benzoic acid and specific 2-oxo acids activate hepatic efflux of glutamate at OAT2  by Pfennig, Till et al.
Biochimica et Biophysica Acta 1828 (2013) 491–498
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamemBenzoic acid and speciﬁc 2-oxo acids activate hepatic efﬂux of glutamate at OAT2
Till Pfennig, Beate Herrmann, Tim Bauer, Edgar Schömig, Dirk Gründemann ⁎
Department of Pharmacology, University of Cologne, Gleueler Straße 24, 50931 Cologne, GermanyAbbreviations: EAAT, excitatory amino acid transporte
acid; LC, liquid chromatography; MS, mass spectrometry;
⁎ Corresponding author. Tel.: +49 221 478 7455; fax
E-mail address: dirk.gruendemann@uni-koeln.de (D
0005-2736/$ – see front matter © 2012 Elsevier B.V. All
http://dx.doi.org/10.1016/j.bbamem.2012.08.026a b s t r a c ta r t i c l e i n f oArticle history:
Received 19 June 2012
Received in revised form 23 August 2012
Accepted 28 August 2012
Available online 7 September 2012
Keywords:
Glutamate transport
SLC22A7
Benzoic acid
2-Oxo acid
LiverThe liver is the principal source of glutamate in blood plasma. Recentlywe have discovered that efﬂux of glutamate
from hepatocytes is catalyzed by the transporter OAT2 (human gene symbol SLC22A7). Organic anion transporter 2
(OAT2) is an integral membrane protein of the sinusoidal membrane domain; it is primarily expressed in liver and
much less in kidney, both in rats and humans. Many years ago, Häussinger and coworkers have demonstrated in
isolated perfused rat liver that benzoic acid or speciﬁc 2-oxo acid analogs of amino acids like e.g. 2-oxo-4-
methyl-pentanoate (‘2-oxo-leucine’) strongly stimulate release of glutamate (up to 7-fold); ‘2-oxo-valine’ and
the corresponding amino acids were without effect. The molecular mechanism of efﬂux stimulation has remained
unclear. In the present study, OAT2 from human and rat were heterologously expressed in 293 cells. Addition of
1 mmol/l benzoic acid to the external medium increased OAT2-speciﬁc efﬂux of glutamate up to 20-fold;
‘2-oxo-leucine’ was also effective, but not ‘2-oxo-valine’. Similar effects were seen for efﬂux of radiolabeled orotic
acid. Expression of OAT2 did not increase uptake of benzoic acid; thus, benzoic acid is no substrate, and
trans-stimulation can be excluded. Instead, further experiments suggest that increased efﬂux of glutamate is caused
by direct interaction of benzoic acid and speciﬁc 2-oxo acids with OAT2. We propose that stimulators bind to a
distinct extracellular site and thereby accelerate relocation of the empty substrate binding site to the intracellular
face. Increased glutamate efﬂux at OAT2 could be the main beneﬁt of benzoate treatment in patients with urea
cycle defects.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The liver continuously releases glutamate into blood [1–3], both
from periportal [4] and pericentral [5] acinus regions. The importance
of hepatic release of glutamate has been documented impressively in
pigs: in a model of acute liver failure induced by portacaval shunt and
hepatic artery ligation, the arterial glutamate concentration, 2 h after
induction, was reduced 6-fold (67 vs. 416 μmol/l) [6]. A marked de-
crease of plasma glutamate was also measured in patients with liver
failure [7,8], cirrhosis [7], or acute on chronic liver disease [7,8]. More-
over, death of patients in septic shock with acute liver dysfunction can
be predicted by signiﬁcantly lowered plasma glutamate concentrations
and lowered glutamate/glutamine ratios [9]. Thus, the liver is the prin-
cipal source of glutamate in plasma. Glutamate absorbed from food nor-
mally has no role here, since it is metabolized by the intestine and
released primarily as alanine [1].
Recently, we have discovered that efﬂux of glutamate from hepato-
cytes is catalyzed by the transporter OAT2 (human gene symbol
SLC22A7) [10]. OAT2 is an integral membrane protein of the sinusoidal
membrane domain [11]; it is primarily expressed in liver and much lessr; GABA, gamma-aminobutyric
OAT, organic anion transporter
: +49 221 478 5022.
. Gründemann).
rights reserved.in kidney, both in rats [11,12] and humans [10]. We have demonstrated
that OAT2 can catalyze both uptake and efﬂux of glutamate. However,
since glutamate is the most abundant intracellular amino acid (reported
concentrations, including hepatocytes, range from 2 to 20 mmol/l [13]),
OAT2 effectively operates as a glutamate efﬂux carrier. Notably, even
without any extracellular exchange substrate, the carrier releases gluta-
mate from cells. Transport of glutamate is independent of sodium ions
and, measured as uptake with OAT2 from rat, has a Km of 1.2 mmol/l
[10]. This moderate afﬁnity reﬂects that the purpose of OAT2 is not to
collect glutamate from extracellular space, but to provide an exit
passage for intracellular cytosolic glutamate. At the same time, the
steep outwardly directed glutamate gradient provides a powerful
driving force for uptake of selected solutes. We have identiﬁed orotic
acid as an excellent and speciﬁc substrate of OAT2 [10].
What is the physiological beneﬁt of releasing glutamate to the
systemic circulation? In mammals, glutamate and glutamine are
extraordinary amino acids, since both are constantly released from
liver into blood (see above). At the same time, there is uptake of gluta-
mine into periportal hepatocytes (= zone of glutamine hydrolysis and
urea production) [14] and uptake of glutamate into pericentral hepa-
tocytes (= zone of glutamine synthesis and release) [5,15]. Gluta-
mine serves as preferred energy fuel for rapidly proliferating cells
(e.g. enterocytes of the intestine; lymphocytes) [16] and as substrate for
ammoniagenesis; it has the highest plasma concentration (e.g. human
artery: 0.57±0.04 mmol/l [7]) of all protein monomers. By contrast,
there is 10–20 times less glutamate in human plasma (e.g. human
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glutamate is only utilized intracellularly. Since glutamate is highly
hydrophilic, its distribution into organs is entirely controlled by
membrane-inserted transport proteins like the sodium-driven EAATs
(excitatory amino acid transporter, SLC1 family). Intracellularly, there
are several enzymes that make use of glutamate [13]; most notably,
glutamine synthetase converts glutamate and ammonia to glutamine.
Ammonia is toxic at elevated levels [17]; inmostmammals, it is normally
disposed of mainly in the urea alias ornithine cycle in liver. Thus, in
healthy humans, urea represents about 80% of urinary nitrogen. However,
much of the nitrogen normally used for urea synthesis can be diverted:
for example, application of benzoic acid or phenylacetic acid reduced
urea to 28% of urinary nitrogen [18]. Because of its high afﬁnity for ammo-
nia, glutamine synthetase is key to an alternative ammonia detoxiﬁcation
pathway: glutamine synthesis is followed by release of non-toxic gluta-
mine into blood and glutamine hydrolysis and ammonia secretion in
the kidney [19]. Important sites of glutamine synthesis frombloodammo-
nia are pericentral hepatocytes [14], muscle [20], and lung [21], but prob-
ably not brain [20]. Another important site of ammonia scavenging may
be platelets, which express glutamine synthetase and EAAT2 [22]. Inter-
estingly, thrombin activation of platelets increases glutamate uptake up
to 9-fold by translocation of EAAT2 to the outer membrane [22]. The
role of glutamate and glutamate transporters for platelets is still unclear.
It can be speculated, however, that plasma concentrations of glutamate
are high enough to sustain efﬁcient local ammonia detoxiﬁcation. On
the whole, there is some evidence to suggest that plasma glutamate is a
key substrate for ammonia detoxiﬁcation via intracellular glutamine
synthetase.
Many years ago, Häussinger and coworkers unexpectedly but
convincingly have demonstrated in isolated perfused rat liver, that
infusion of benzoic acid or particular 2-oxo acid analogs of amino
acids like e.g. ‘2-oxo-leucine’ strongly stimulates release of glutamate
(up to 7-fold) [2,4]. The corresponding amino acids (e.g. leucine) were
without effect. 2-Oxo acids are enzymatically derived from amino
acids by replacing the alpha-amino group with a double-bonded
oxygen; see Materials and methods for precise chemical names.
Up to now, the molecular mechanism of efﬂux stimulation is
unclear. One of several suggestions then was the involvement of a
transport protein.
It was our aim to explore whether benzoic acid and 2-oxo acids in-
teract speciﬁcally with OAT2 to stimulate glutamate efﬂux and, if so,
to deﬁne the mechanism.
2. Materials and methods
2.1. Plasmid constructs
The cDNA coded by the human SLC7A11 gene (xCTh) was generated
by RT-PCR, cloned into pUC19, fully sequenced, and inserted into expres-
sion vector pEBTetD. pEBTetD is an episomal Epstein–Barr plasmid vector
for doxycycline-inducible protein expression in human cell lines based on
the simple tetracycline repressor [23]. With e.g. the ergothioneine trans-
porter (SLC22A4), this system provides a high rate of carrier-mediated
transport in the on-state (doxy(+)) (=100%) and a low rate (4%) in
the off-state (doxy(−)) (=leak expression) [23]. The amino acid se-
quence of our xCTh clone matches GenBank entry NM_014331. The 5′-
interface between pEBTetD and cDNA is GTTTAAACTT AAGCTT GCCACC
ATGGTCAGAAAGCCTGTTGTGTC (polylinker in bold, cDNA underlined);
the 3′-interface is TGTACCAGAAGAAGATAAGTTATGAGCGGCCGC GGGGC
AGT. Constructs for expression of OAT2 from human (OAT2h) and rat
(OAT2r) have been described before [10].
2.2. Cell culture
293 cells (ATCC CRL-1573; also known as HEK-293 cells), a
transformed cell line derived from human embryonic kidney, weregrown at 37 °C in a humidiﬁed atmosphere (5% CO2) in plastic culture
ﬂasks (Falcon 3112, Becton Dickinson, Heidelberg, Germany). The
growthmediumwas Dulbecco's Modiﬁed Eagle Medium (Life Technol-
ogies 31885–023, Invitrogen, Karlsruhe, Germany) supplemented with
10% fetal calf serum (PAA Laboratories, Cölbe, Germany). Medium was
changed every 2–3 days and the culture was split every 5 days.
Stably transfected cell lines were generated as reported previously
[23]. As there is no integration of vector pEBTetD into the genome, clonal
isolation of transfected cells is not necessary; we thus use cell pools
rather than single cell clones. Cell culture medium always contained
3 μg/ml puromycin (PAA Laboratories) to assure plasmid maintenance.
To turn on protein expression, cells were cultivated for at least 20 h in
regular growth medium supplemented with 1 μg/ml doxycycline
(195044, MP Biomedicals, Eschwege, Germany).
2.3. Transport assays
Formeasurement of solute uptake, cellswere grown in surface culture
on 60 mmpolystyrol dishes (Nunclon 150288, Nunc, Roskilde, Denmark)
precoated with 0.1 g/l poly-L-ornithine in 0.15 M boric acid–NaOH,
pH 8.4. Cells were used for uptake experiments at a conﬂuence of at
least 70%. Uptake was measured at 37 °C. Uptake buffer contained
125 mmol/l NaCl, 25 mmol/l HEPES–NaOH pH 7.4, 5.6 mmol/l (+)
glucose, 4.8 mmol/l KCl, 1.2 mmol/l KH2PO4, 1.2 mmol/l CaCl2, and
1.2 mmol/l MgSO4. All buffers for direct measurement of analytes by
LC–MS/MS were made without KH2PO4 to avoid interference.
Sodium-free buffer contained N-methyl-D-glucosamine hydrochloride
instead of sodium chloride; pH was adjusted with TRIS instead of
NaOH. In uptake experiments, after preincubation for at least 20 min in
4 ml of uptake buffer, the buffer was replaced with 2 ml of substrate in
uptake buffer; the total substrate concentration if not indicated otherwise
was 0.1 μmol/l in radiotracer assays and 10 μmol/l with unlabeled com-
pounds. Incubation was stopped after 1 min by rinsing the cells four
times each with 4 ml ice-cold uptake buffer. Radioactivity was deter-
mined, after cell lysis with 0.1% v/v Triton X-100 in 5 mmol/l Tris–HCl
pH 7.4, by liquid scintillation counting. For LC–electrospray ionization–
MS/MS analysis, cells were lysed with methanol and stored at −20 °C.
After centrifugation (1 min, 16,000×g, 20 °C) of thawed lysates, 10 μl
samples were analyzed by LC–MS/MS on a triple quadrupole mass spec-
trometer (4000 Q TRAP, Applied Biosystems, Darmstadt, Germany). The
following LC conditionswere used for glutamate: ZIC-HILIC column (par-
ticle size 5 μm, diameter×length=2.1 mm×100 mm; Dichrom, Marl,
Germany); A: 0.1% formic acid, B: 0.1% formic acid in acetonitrile; gradi-
ent: 0.3 ml/min, 85% B at 0 min, 20% B at 4 min, 20% B at 5 min, 85% B
at 7 min, stop at 8 min. Atmospheric pressure ionization with positive
or negative electrospray was used. For quantiﬁcation (scan time
150 ms), the optimal collision energy for nitrogen-induced fragmenta-
tion in the second quadrupole was determined for each analyte. From
the product ion spectra, the following fragmentationswere chosen for se-
lected reaction monitoring (m/z parent, m/z fragment, collision energy
(V)): glutamate: 148, 84, 25; positive ion detection. For each analyte,
the area of the intensity vs. time peak was integrated. Linear calibration
curveswere constructed fromat least six standardswhichwere prepared
using control cell lysates as solvent. Sample analyte content was calcu-
lated from the analyte peak area and the slope of the calibration curve,
obtained by weighted linear regression.
Protein was measured by the BCA assay (Pierce) with bovine
serum albumin as standard. The protein content of MS samples was
estimated from 3 matched cell dishes.
2.4. Calculations and statistics
All results are given as arithmetic mean±SEM with at least n=3;
all assays were at least performed twice, on separate days. EC50 and Ki
values are given as geometric mean with 95% conﬁdence interval.
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Fig. 2. Time course — benzoic acid stimulates OAT2h-catalyzed glutamate efﬂux. 293
cells in paired dishes, stably transfected with pEBTetD/OAT2h, were cultivated for
20 h in the presence (to express the transporter) or absence of 1 μg/ml doxycycline
in growth medium. Cells were washed twice with prewarmed sodium-free uptake
buffer, and then incubated (37 °C)with 2 ml sodium-free uptake buffer without (control)
or with 1 mmol/l benzoic acid. At the indicated time points, consecutive buffer samples
(0.2 ml) were collected and analyzed by LC–MS/MS for released glutamate. The model
for ﬁtting the topmost data series was y=y0+ymax∗(1−exp(−k∗x)); a straight line
was ﬁtted to the other series.
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Fig. 1. Benzoic acid stimulates efﬂux of glutamic acid and orotic acid from OAT2h-expressing cells. Transfected 293 cells were grown in dishes and incubated overnight with
doxycyclin in standard culture medium to express OAT2 from human. (A) Cells were washed twice with prewarmed uptake buffer, and then incubated for 3 min (37 °C) with uptake
buffer (control) or 1 mmol/l of the indicated compounds in uptake buffer (1 ml). Finally, a buffer sample (0.7 ml) was collected and analyzed by LC–MS/MS for released glutamate.
(B) Cells were incubated (1 h, 37 °C) with 100 μmol/l 3H-orotic acid in uptake buffer, washed twice with ice-cold uptake buffer, and then incubated for 3 min (37 °C) as above. Buffer
samples (0.7 ml) were analyzed for released 3H-orotic acid by liquid scintillation counting.
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2.5. Chemicals
Deﬁnitions of informal names for 2-oxo acids are: ‘2-oxo-leucine’:
2-oxo-4-methyl-pentanoate, 2-oxo-4-methyl-valerate, 2-oxoisocaproate;
‘2-oxo-valine’: 2-oxo-3-methyl-butanoate, 2-oxo-3-methyl-butyrate,
2-oxoisovalerate.
Unlabeled compounds are: benzoic acid (Art. 136, Merck, Darmstadt,
Germany), L-cystine (C-8755, Sigma-Aldrich, Munich, Germany),
L-glutamic acid potassium salt monohydrate (G-1501, Sigma-Aldrich),
and orotic acid monohydrate (O-8402, Sigma-Aldrich). All other
chemicals were at least of analytical grade.
Radiotracers are: benzoic acid (H-3, 0.74 kBq/pmol, ART-782, ARC,
St. Louis, MO, USA), L-glutamic acid (H-3, 2.2 kBq/pmol, ART-132,
ARC), and orotic acid (H-3, 0.47 kBq/pmol, MT-668, Moravek, Brea,
CA, USA).
3. Results
3.1. Benzoic acid and 2-oxo-leucine stimulate OAT2-catalyzed efﬂux
OAT2 from human (OAT2h) and rat (OAT2r) were expressed in
293 cells as before [10] using the pEBTetD expression vector [23].
To determine the release of glutamate from OAT2h-expressing cells,
monolayers grown in dishes were incubated with buffer at 37 °C.
After 3 min, buffer samples were collected and analyzed for glutamate
content by LC–MS/MS. Under these control conditions, the majority of
released glutamate is transported by OAT2 [10]. As positive control, ad-
dition of the OAT2 substrate orotic acid (at 1 mmol/l) to the buffer
strongly increased efﬂux of glutamate (Fig. 1A). Benzoic acid or
‘2-oxo-leucine’, known stimulators of hepatic glutamate release, also
markedly stimulated efﬂux of glutamate (Fig. 1A). By contrast, the
natural amino acid leucine had no effect. Similar effects were seen
when the efﬂux activity of OAT2h was assayed with radiolabeled
orotic acid after preloading of cells (Fig. 1B).
A time course of glutamate efﬂux via OAT2h (Fig. 2) revealed a
20-fold increase of initial efﬂux rate caused by 1 mmol/l benzoic
acid (slope between 3 and 10 min: 14.7 nmol min−1 mg protein−1)
versus control (0.72 nmol min−1 mg protein−1). There was no con-
tinuous release of glutamate from control cells (OAT2h expression
off).3.2. Mechanism of stimulation of efﬂux by benzoic acid
Orotic acid in the buffer stimulates efﬂux of glutamate [10] by the
well-known mechanism called trans-stimulation or accelerated ex-
change (see e.g. chapter 4 in [24]); in our case, release of intracellular
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Fig. 3. Benzoic acid is not transported by OAT2. 293 cells in paired dishes, stably transfectedwith pEBTetD/OAT2r or pEBTetD/OAT2h, were cultivated for 20 h in the presence (to express
the transporter) or absence (control) of 1 μg/ml doxycycline in growth medium. After preincubation and washing, cells were incubated (1 min, 37 °C) with 0.1 μmol/l of the indicated
3H-labeled compound in sodium-free uptake buffer. Cells were then washed and lysed; lysates were analyzed by liquid scintillation counting.
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substrate accelerates the return of the binding site to the intracellular
face (compared to an unoccupied binding site; see Fig. 9). If benzoic acid
stimulates efﬂux by the samemechanism, then it must be a substrate of
OAT2. However, with 3H-benzoic acid, no difference was measured for
the uptake into cells with or without expression of OAT2h and OAT2r
(Fig. 3). In paired dishes, the presence of functional transporters was
demonstrated with the substrates orotic acid and glutamate (Fig. 3).
Moreover, no difference was seen with unlabeled benzoic acid
(10 μmol/l, 1 min uptake time, OAT2r cells) and LC–MS/MS quantitation
(not shown). Thus, benzoic acid is not a substrate of OAT2, and stimula-
tion of efﬂux cannot be explained by trans-stimulation.
An experiment was made to see whether stimulation of efﬂux by
benzoic acid is independent from trans-stimulation of efﬂux by orotic
acid. Stimulation of efﬂux of 3H-orotic acid by the simultaneous presence
of benzoic acid and orotic acid (each at 1 mmol/l) was not stronger than
by benzoic acid alone, both for OAT2h and OAT2r (Fig. 4). We conclude
that the two mechanisms are not entirely independent.
Stimulation of efﬂux of 3H-orotic acid wasmeasured as a function of
benzoic acid concentration (Fig. 5A); the EC50 was 116 (95% conﬁdence
interval: 50–267) μmol/l for OAT2h and 113 (58–220) μmol/l for OAT2r.
By contrast, the Ki-values for inhibition of uptake of 3H-orotic acid by
benzoic acid were much higher, i.e. 681 (95% conﬁdence interval:
485–955) μmol/l for OAT2h and 638 (488–838) μmol/l for OAT2r
(Fig. 5B). This suggests that the efﬂux stimulating binding site for3H-Orotic acid efflux
(nmol min-1 mg protein-1)
0 2 4 6 8
OAT2 human
+ Benzoic acid
+ Orotic acid
Control
+ both
Fig. 4. Concurrent incubation with orotic acid and benzoic acid does not increase efﬂux of 3Hbenzoic acid on the carrier protein is different from the substrate
binding site.
To examinewhether benzoic acid has an indirect effect on glutamate
efﬂux (e.g. inhibition of glutamate reuptake), the cystine/glutamate
exchanger xCT (gene symbol SLC7A11) from human was cloned
and expressed in 293 cells. This carrier couples efﬂux of glutamate
to uptake of cystine [25,26]. As expected, extracellular cystine
(1 mmol/l) strongly stimulated glutamate efﬂux via xCT (Fig. 6).
However, by contrast to OAT2h, benzoic acid had no effect on xCT ac-
tivity. This suggests that benzoic acid stimulates OAT2 directly.
3.3. Speciﬁcity of ligand-stimulated efﬂux
The structural constraints of the benzoic acid binding site were ex-
amined by testing a panel of structurally related compounds (all at
1 mmol/l) for stimulation of efﬂux of 3H-orotic acid (Fig. 7). Marked
stimulation, albeit weaker than with benzoic acid, was observed, both
at OAT2h and OAT2r, with nicotinic acid, salicylic acid, acetylsalicylic
acid, 3-aminobenzoic acid and 4-aminobenzoic acid. Compounds
more distant in structure to benzoic acid like quinolinic acid,
quinoline-3-carboxylate, 2-oxoglutarate, p-aminohippurate, and pro-
line were without clear effect. Interestingly, GABA stimulated OAT2
from human as strongly as benzoic acid, but was completely inactive
on OAT2 from rat. In an uptake experiment with LC–MS/MS quantita-
tion, GABA (10 μM, 1 min) was not a substrate of OAT2h (not shown).10 0 2 4 6 8 10
OAT2 rat
-orotic acid further. See legend to Fig. 1B for setup; both acids were used at 1 mmol/l.
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Fig. 5. EC50 of benzoic acid for stimulation of glutamate efﬂux differs from Ki for inhibition of uptake of orotic acid. (A) Stimulation of efﬂux of 3H-orotic acid as a function of benzoic
acid concentration. See legend to Fig. 1B for setup. The following equation was ﬁt to raw data to estimate the EC50: y=y0+(ymax−y0)∗x/(EC50+x); the graph shown is based on
(y−y0)/(ymax−y0)=x/(EC50+x). (B) Uptake of 3H-orotic acid as a function of benzoic acid concentration. Transfected cells in dishes with expression of OAT2h or OAT2r were
incubated (1 ml) for 1 min with 0.1 μmol/l 3H-orotic acid in uptake buffer plus benzoic acid as indicated. The model for ﬁtting was y=1/(1+x/IC50). Ki=IC50, since the substrate
concentration was much smaller than the Km (200 μmol/l [10]).
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urea, ammonium, and glutamine failed to affect efﬂux of unlabeled glu-
tamate via OAT2h (not shown); stimulation by GABA was conﬁrmed.
Fig. 8 shows results from compounds related to amino acids with and
without a phenyl residue. Cinnamic acid caused stimulation of efﬂux
as potent as benzoic acid.4. Discussion
Up to now, the molecular mechanism of stimulation of glutamate
efﬂux from liver into blood by benzoic acid [2] and speciﬁc 2-oxo acids
[4,27] has been unclear. Our results reveal that the effects observedwith
isolated perfused rat liver can be mirrored by heterologous expression
of the transporter OAT2 in 293 cells. OAT2 efﬁciently transports gluta-
mate and orotic acid and is expected to function as glutamate efﬂux
transporter in periportal and pericentral hepatocytes [10].G
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Fig. 6. Benzoic acid does not stimulate efﬂux of glutamate at xCT. Transfected 293 cells in dis
were washed twice with prewarmed sodium-free uptake buffer, and then incubated for 10
buffer (buffer control) or 1 mmol/l of the indicated compounds in buffer (1 ml). Finally, a bAlthough OAT2h and OAT2r show considerable differences in the
efﬁciency of transport of several substrates [10], stimulation works
not only with the rat transporter, but also with OAT2 from human.
Our results are fully consistent with the data from isolated perfused
rat liver: 1) the magnitude of stimulation of total efﬂux in our experi-
ments (3–6-fold) is similar to the rat liver data; 2) efﬂuxwas stimulated
only by speciﬁc 2-oxo acids;most notably, ‘2-oxo-leucine’was effective,
while ‘2-oxo-valine’, although very similar in structure, was not; and 3)
at ﬁrst glance, our EC50 of efﬂux stimulation (0.11 mmol/l) disagrees
with the reported value of 0.8 mmol/l (Table 1 in [2]); however, a plot
of peak height or peak area (measured in Fig. 1a in that publication)
as a function of benzoic acid concentration, yielded with a simple
model (y=Vmax∗x/(EC50+x)) and non-linear regression an EC50 of
0.17 or 0.2 mmol/l, respectively. Thus, the features of OAT2 replicate
the organ data.
A mechanistic hypothesis has to explain several details. 1) Benzoic
acidmodulates OAT2 efﬂux activity in general: stimulation is not limitedSLC7A11 human
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Fig. 7. Stimulation of 3H-orotic acid efﬂux in 293 cells expressing OAT2 from human or
rat by compounds related in structure to benzoic acid. See legend to Fig. 1B for setup;
all compounds were used at 1 mmol/l.
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strate (Fig. 1). 2) The effect is not indirect, since efﬂux of glutamate
via xCT (SLC7A11) is not affected by benzoic acid (Fig. 6). 3) Benzoic
acid is not transported into the cell by OAT2 (no increase of uptake
of radiotracer by expression of OAT2; Fig. 3); this rules out
trans-stimulation. 4) Trans-stimulation by orotic acid and efﬂux
stimulation by benzoic acid are not independent, since the simulta-
neous presence of orotic acid and benzoic acid had no bigger effectRelative 3H-orotic acid efflux (%)
+ Cinnamic acid
+ '2-Oxo-Leucine'
+ Phenylacetate
+ Oxaloacetate
+ Acetoacetate
+ Phenylpyruvate
+ Pyruvate
+ '2-Oxo-valine'
+ Leucine
+ Valine
+ Benzoic acid
Control
0 100 200 300 400
rat
human
OAT2
Fig. 8. Stimulation of 3H-orotic acid efﬂux in 293 cells expressing OAT2 from human or
rat by compounds related to amino acids and 2-oxo acids. See legend to Fig. 1B for
setup; all compounds were used at 1 mmol/l.than either compound alone (Fig. 4). Thus, the mechanism of efﬂux
stimulation by benzoic acid, although different from trans-
stimulation, could affect the same part of the transport cycle, i.e. re-
location of the substrate binding site to the intracellular membrane
face. 5.) Comparison of binding afﬁnities (EC50 vs. Ki) suggests a
binding site for benzoic acid separate from the substrate binding
site (Fig. 5).
We propose the mechanism shown in Fig. 9: benzoic acid binds to a
distinct extracellular site (designated ‘benzoate site’ in the remainder)
and thereby accelerates relocation of the empty substrate binding
site. This model explains why addition of orotic acid to a saturating
concentration of benzoic acid does not increase efﬂux further. Note
that this mechanism is different from activation of uptake at EMT
(SLC22A3) from rat, where we have proposed 2 interacting sub-
strate binding sites to explain stimulation by inhibitors and sub-
strates [28].
In order to deﬁne the speciﬁcity of the benzoate site, we have tested
compounds beyond the known stimulators. Several compounds related
in structure to benzoic acid clearly stimulated efﬂux, albeit less potently
than benzoic acid: nicotinic acid, salicylic acid, acetylsalicylic acid,
3-aminobenzoic acid and 4-aminobenzoic acid (Fig. 7). A negative
charge is required (compare nicotinamide and nicotinic acid); an
ortho amino group is not tolerated (2-aminobenzoic acid). No 2-oxo
acid better than ‘2-oxo-leucine’ was found, but cinnamic acid was
as effective as benzoic acid (Fig. 8). The biggest surprise was the
zwitterion GABA, which is as effective as benzoic acid on the
human transporter, but entirely inactive on the rat carrier (Fig. 7).
Thus, potent new stimulators of glutamate efﬂux can now be identi-
ﬁed by simple heterologous expression of OAT2. Note, however, that
each stimulator must be tested for transport in order to rule out
trans-stimulation.
Stimulation of speciﬁc efﬂux (i.e. the fraction of total efﬂux catalyzed
by OAT2) of glutamate by benzoic acid is very high, up to 20-fold in our
experiments (see Figs. 2 and 6). The decrease of efﬂux rate over time
(Fig. 2) may be caused by depletion of the cytosolic glutamate pool. In-
deed, increased glutamate export by the liver has been shown to cause
such a depletion and hence a decrease in urea production [4]; in this
way, an increase of 2-oxo acids like ‘2-oxo-leucine’ in blood during
starvation [1,29] can be translated into retention of ammonia and
transfer (glutamate is made of ammonia and 2-oxo-glutarate) to
other organs. In other words, stimulation of hepatic glutamate efﬂux
by (some) natural 2-oxo acids provides physiological beneﬁt by
sparing nitrogen.
Stimulation of hepatic glutamate efﬂux by external ligands like
benzoic acid has therapeutic beneﬁt in vivo. Benzoic acid enters the
human body as a natural constituent in plants, with high amounts in
fruits and berries, and as a result of the widespread use of monosodium
benzoate as a food preservative. Since 1979, sodium benzoate has also
been used to combat ammonia toxicity in patients with genetic defects
in the urea cycle. Although the clinical use of benzoate improves out-
come, the mode of action has remained uncertain [18]. Our results sub-
stantiate the notion that a controlled increase in glutamate export
promotes extrahepatic disposal of waste nitrogen [18]: vascular gluta-
mate promotes synthesis of glutamine (see Introduction) followed by
release, renal uptake, and hydrolysis of glutamine, and urinary excretion
of ammonium [30]. Our ﬁndings are clinically relevant, since, at thera-
peutic dosage, the average benzoate concentration in plasma may be
higher (e.g. Fig. 2 in [31]) than the EC50 from the present study (Fig. 5A).
In summary, our results imply that marked stimulation of hepatic
efﬂux of glutamate by benzoic acid and speciﬁc 2-oxo acids is caused by
direct interactionwith OAT2, a transporter of the sinusoidal membrane.
We propose that those stimulators bind to a distinct extracellular site
and thereby accelerate relocation of the empty substrate binding site
to the intracellular face. Increase of glutamate efﬂux at OAT2 could be
the main beneﬁt of benzoate treatment in patients with urea cycle
defects.
Glu
inside
outside
Glu
Basic transport cycle
BenzBenz
Trans-stimulation by orotic acid uptake
Stimulation by benzoic acid binding
OrotOrot
Orot
Benz
Glu
Fig. 9. Schematic diagram of stimulation of efﬂux by benzoic acid. Number of parallel arrows indicates speed (1=slow; 5=fast); dotted lines indicate ﬁnished movement. A full
transport cycle (4 states) for efﬂux of glutamate (Glu) is shown in the upper half; extracellular orotic acid (Orot) or benzoic acid (Benz) accelerate one (slow) step, i.e. access from
outside changes to access from inside. Our scheme suggests 2 substrate binding sites per transporter entity, because transport of glutamate, but not of orotic acid, is abolished in
OAT2h mutant E441Q [10]; however, these sites may overlap.
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